Curci D, Lucafò M, Cifù A, et al. - Thirty-two serum samples from 19 children with inflammatory bowel disease (IBD) treated with infliximab was examined to contrast two point-of-care (POC) devices for quantification of serum infliximab concentration with two confirmed enzyme-linked immunosorbent assay (ELISA) assays in children with IBD. Classification of outcomes according to therapeutic intervals exhibited superior agreement among pairs of assay. POC infliximab assays presented a genuine agreement with traditional ELISA assays. For real-time therapeutic drug monitoring, in children treated with infliximab, POC devices may designate a viable option.